Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Uterine Cervical Neoplasms 4Neoplasms 4Prostatic Neoplasms 3Glioma 3Glioblastoma 3Uterine Cervical Dysplasia 2Sarcoma 2Breast Neoplasms 2Atypical Squamous Cells of the Cervix 2Astrocytoma 2Xeroderma Pigmentosum 1Triple Negative Breast Neoplasms 1Trichothiodystrophy Syndromes 1Squamous Intraepithelial Lesions 1Spinal Cord Neoplasms 1Sexuality 1Pilonidal Sinus 1Peritoneal Neoplasms 1Pelvic Organ Prolapse 1Ovarian Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyoma 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Restraint, Physical × 1 year × Clear all
NCT06648278 2026-01-13

COUNTS2

University of California, San Francisco

Phase NA Recruiting
260 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡